# Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

> **NCT05060419** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Complicated Urinary Tract Infection
- Acute Pyelonephritis

## Interventions

- **DRUG:** Meropenem- FL058
- **DRUG:** Piperacillin -tazobactam
- **DRUG:** Saline
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT05060419
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-08
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-08-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060419, "Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05060419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*